临床终点
安慰剂
医学
内科学
随机化
临床试验
人口
最小临床重要差异
布洛芬
临床研究阶段
初级保健
重复措施设计
子群分析
代理终结点
无症状的
人口研究
前瞻性队列研究
方差分析
加药
联合疗法
探索性分析
随机对照试验
痴呆
意向治疗分析
平均差
外科
基因型
作者
David R. Elmaleh,Atul Gupta,David Brazier,William Garofano,Peter S. Conti
标识
DOI:10.1177/13872877261498247
摘要
Background This study tested ALZT-OP1 (inhaled cromolyn 17.1 mg and oral ibuprofen 10 mg) in early Alzheimer's disease (AD). Objective To evaluate the efficacy and safety of ALZT-OP1 in early AD. Methods Cognite was a Phase III, double-blind, placebo-controlled, four-arm factorial trial in 619 participants with early AD (cerebrospinal fluid [CSF] amyloid-β 42 (Aβ 42 ) 180–690 pg/mL; Clinical Dementia Rating–Global 0.5). Randomization was 1:1:1:1 to cromolyn, ibuprofen, combination therapy, or placebo for 72 weeks. The primary endpoint was change from baseline to Week 72 in Clinical Dementia Rating–Sum of Boxes (CDR-SB), comparing combination versus each monotherapy. Secondary and exploratory endpoints included comparisons with placebo, subgroup analyses by apolipoprotein E4 ( APOE4 ) status, Mini-Mental State Examination scores, CSF biomarkers, and safety. Results In the modified intent-to-treat population (n = 594), the primary endpoint was not met. No statistically significant difference was found between combination and cromolyn (difference 0.16, 95% CI −0.58 to 0.90; p = 0.675) or ibuprofen (0.40, 95% CI −0.32 to 1.13; p = 0.276). APOE4 non-carriers receiving combination therapy showed a numerical benefit versus placebo (least-squares mean difference −0.96; 95% CI −2.00 to 0.08; p = 0.069), although this was not statistically significant. ALZT-OP1 was safe and well tolerated. Conclusions ALZT-OP1 did not demonstrate efficacy in an unselected early AD population. The numerical benefit observed in APOE4 non-carriers warrants prospective evaluation in a genotype-stratified trial. ALZT-OP1 was safe and well tolerated over 72 weeks, and the study provides insights for future AD trial design. The study is registered at ClinicalTrials.gov ( https://clinicaltrials.gov/study/NCT02547818 ; NCT02547818).
科研通智能强力驱动
Strongly Powered by AbleSci AI